Phase III Study of Lilly’s Foundayo, Reaffirms Cardiovascular and Overall Safety Profile, Plus Improvements to Cardiometabolic Health

Why It Matters

The data positions Foundayo as a potentially safer, once‑daily oral alternative for high‑risk type 2 diabetes patients, expanding treatment options beyond injectable GLP‑1 therapies and influencing cardiovascular risk management strategies.

Key Takeaways

• Foundayo met primary endpoint, non‑inferior MACE‑4 vs insulin glargine
• Showed superior A1C reduction and weight loss at 52 weeks
• All‑cause mortality risk lower for Foundayo, though not multiplicity‑adjusted
• Trial enrolled >2,700 patients across 15 countries, longest Foundayo study
• Lilly plans FDA submission by Q2 using National Priority Review voucher

Pulse Analysis

The ACHIEVE‑4 trial marks a pivotal moment for oral GLP‑1 therapeutics, a class traditionally dominated by injectable formulations. Foundayo’s ability to match insulin glargine on major adverse cardiovascular events while delivering a daily pill without food or water restrictions addresses a long‑standing adherence barrier for patients with type 2 diabetes and obesity. As clinicians increasingly prioritize cardiovascular outcomes, an oral agent that meets safety benchmarks could reshape prescribing patterns, especially for patients reluctant to adopt injectable regimens.

Beyond safety, the trial’s efficacy signals are compelling. Participants on Foundayo experienced statistically significant A1C reductions and meaningful weight loss at the one‑year mark, with these advantages maintained through two years of therapy. Although the mortality analysis was not adjusted for multiple comparisons, the observed lower all‑cause death rate adds a persuasive narrative for clinicians seeking holistic benefits. The study’s scale—over 2,700 patients across 15 nations—provides robust, generalizable evidence that may accelerate acceptance among payers and guideline committees.

Regulatory momentum is now on Lilly’s side. By leveraging a National Priority Review voucher, the company aims to expedite FDA approval, potentially bringing the first oral GLP‑1 to the U.S. market within months. If approved, Foundayo could capture market share from both injectable GLP‑1s and traditional insulin therapies, especially as insurers favor agents that reduce cardiovascular events and overall mortality. Competitors will need to respond, either by advancing their own oral candidates or by emphasizing differentiated delivery mechanisms, making the next few quarters critical for the cardiometabolic drug landscape.